ADVERTISEMENT
Latest Blogs, Articles, and More
The FDA Approves Its First Biosimilar, Zarxio
The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications.
Views on Evolving Chemotherapy Options—and Beyond—in TNBC
BY ANNA AZVOLINSKY, PHD
Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.
Prior Cancer History Should Not Exclude Patients With Advanced Lung Cancer From Clinical Trials
BY CHRISTINA IZZO
Results of a new study may help more lung cancer patients be eligible to participate in clinical trials.Researchers found that previously having cancer does not impact clinical outcomes in lung cancer patients.
A Beautiful Life of Cancer Denial
BY SUSAN FARISS
Living in denial is sometimes not such a bad idea, especially when it comes to cancer.
 FDA Approves Opdivo for Lung Cancer
BY JASON M. BRODERICK
The Food and Drug Administration has approved the anti–PD-1 agent Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). The approval comes three months ahead of the FDA’s scheduled decision date.
Special Feature
ADVERTISEMENT
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$